Vaccinia clinical trials
The registry lists 54 studies for Vaccinia across more than 10 countries. 6 are recruiting or about to start. 8 of them are mainly about Vaccinia (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-21.
Get an email when these change. Save the Vaccinia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (16) · Jennerex Biotherapeutics (7) · Emergent BioSolutions (4) · Genelux Corporation (4) · Groupe Hospitalier Sud Ile-de-France (2) · Genelux GmbH (2) · Bavarian Nordic (1) · Hangzhou Converd Co., Ltd. (1)
What is being tested here
Drugs under test in Vaccinia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Dec 2026Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) · Phase 3 · Genelux Corporation
- Jan 2027IDOV-Immune for Advanced Solid Tumors · ViroMissile, Inc.
- Feb 2027Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer · Genelux Corporation
Who these studies take
Of the 6 Vaccinia studies recruiting now, 4 (67%) set no upper age limit and 2 (33%) stop at 75 or younger. 0 (0%) take children under 18. 1 (17%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 6 (100%) | 5 (83%) |
| 30 | 6 (100%) | 5 (83%) |
| 40 | 6 (100%) | 5 (83%) |
| 50 | 6 (100%) | 5 (83%) |
| 65 | 6 (100%) | 5 (83%) |
| 75 | 5 (83%) | 4 (67%) |
| 85 | 4 (67%) | 3 (50%) |
Across all 54 studies, recruiting or not: 43% stop at 75 or younger and 39% at 65; 17% take children; 11% are for women only and 2% for men only; 48% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 54. Browse all 54 → or search them.
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)RecruitingNCT05281471Phase 31 country
- IDOV-Immune for Advanced Solid TumorsRecruitingNCT06910657Phase 12 countries
- Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerRecruitingNCT06463665Phase 21 country
- Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic CancerRecruitingNCT07006077Phase 21 country
- Evaluation of Patients' Knowledge of Their Vaccination Status and Their Relationship to Vaccination at Melun HospitalRecruitingNCT066167531 country
- Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal TumorsRecruitingNCT07001592Phase 11 country
- Evaluating the Human Immune Response to the JYNNEOS VaccineActive, not recruitingNCT06366672Early Phase 11 country
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal CarcinomaCompletedNCT01394939Phase 1/23 countries
- A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular CarcinomaCompletedNCT01171651Phase 21 country
- A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed SorafenibCompletedNCT01387555Phase 27 countries
- Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal CarcinomaCompletedNCT01380600Phase 11 country
- Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerCompletedNCT02759588Phase 1/21 country
- Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib AloneCompletedNCT02562755Phase 316 countries
- A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic CarcinomaCompletedNCT00629759Phase 11 country
- JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the CongoCompletedNCT02977715Phase 31 country
- Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-LactCompletedNCT05376527Phase 11 country
- A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsTerminatedNCT04725331Phase 1/22 countries
- A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal CarcinomatosisCompletedNCT01443260Phase 1/21 country
- Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid TumorsCompletedNCT00794131Phase 11 country
- A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid TumorsCompletedNCT03954067Phase 11 country
- Evaluation of Healthcare Workers Knowledge Regarding Their Vaccination Status at Melun HospitalCompletedNCT066507221 country
- Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)CompletedNCT009285771 country
- ACAM2000® Myopericarditis RegistryCompletedNCT013950821 country
- Safety Surveillance Study of ACAM2000® Vaccinia VaccineCompletedNCT009277191 country
- Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated AdultsCompletedNCT00053482Phase 21 country
- Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In ServiceStatus unknownNCT050925681 country
- A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160CompletedNCT00000745Phase 11 country
- A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg DoseCompletedNCT00001056Phase 11 country
- A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160CompletedNCT00000956Phase 11 country
- A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination SchedulesCompletedNCT00001043Phase 11 country
- A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive IndividualsCompletedNCT00001026Phase 11 country
- A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope VaccinesCompletedNCT00000746Phase 11 country
- A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated SchedulesCompletedNCT00000957Phase 11 country
- A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160CompletedNCT00000757Phase 11 country
- A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency VirusCompletedNCT00000683Phase 11 country
- A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive IndividualsCompletedNCT00000633Phase 11 country
- A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)CompletedNCT00000631Phase 11 country
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)CompletedNCT00000767Phase 11 country
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.CompletedNCT00000866Not applicable1 country
- Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)CompletedNCT00000630Phase 11 country
- Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA VirusesCompletedNCT01143181Phase 31 country
- A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®CompletedNCT01913353Phase 31 country
- The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 YearsStatus unknownNCT04022148
- SIGA-246 to Treat SmallpoxWithdrawnNCT00303225Phase 11 country
- Evaluation and Treatment of Eye Complications of Vaccinia VaccinationCompletedNCT00081835Phase 21 country
- Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric PatientsCompletedNCT01169584Phase 11 country
- Safety Study of Modified Vaccinia Virus to CancerCompletedNCT00574977Phase 11 country
- Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsCompletedNCT00625456Phase 12 countries
- Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck CancerCompletedNCT01584284Phase 11 country
- Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer OriginWithdrawnNCT02017678Phase 21 country